IGC Pharma (NYSE American: IGC) Alzheimer's Drug Gains Attention After Ascendiant Capital Raises Price Target

IGC Pharma's Alzheimer's program has drawn renewed investor attention after Ascendiant Capital reiterated a BUY rating and lifted its 12-month price target to $5.50. On June 9, 2026, the stock traded intraday as high as $0.30 and closed at $0.285, with volume reaching 1,308,653 shares. Ascendiant cites milestones likely in the second half of 2026, including completing enrollment and advancing the Phase 2 CALMA trial evaluating IGC‑AD1, along with the rollout of the company’s AI platform beta program. IGC recently reported over 80% patient enrollment in CALMA and expects completion in mid-to-late 2026. The pipeline includes five Alzheimer's candidates, led by IGC‑AD1, with preclinical programs such as TGR‑63. Investors weigh continued clinical progress, potential data readouts, and AI initiatives as catalysts in a high‑risk, high‑reward sector.